Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

334
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
334
Positron Emission Tomography01:29

Positron Emission Tomography

6.6K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
6.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Apalutamide + Abiraterone Acetate plus Prednisone + Leuprolide with Stereotactic, Ultra-Hypofractionated Radiation in Very High-Risk Prostate Cancer: A Single-Arm, Phase 2 Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Total intravenous anaesthesia in emergency surgery: a narrative review.

Anaesthesia·2025
Same author

Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 Trial.

European urology oncology·2025
Same author

Tau phosphorylation at Alzheimer's disease biomarker sites impairs its cleavage by lysosomal proteases.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Method to determine the nadir PSA following partial gland ablation.

BJUI compass·2025
Same author

Stereotactic implantation of diffusing alpha-emitters radiation therapy sources in the swine brain: a potential new focal therapy for brain tumors.

Journal of neuro-oncology·2025

Related Experiment Video

Updated: Nov 28, 2025

Models of Bone Metastasis
08:49

Models of Bone Metastasis

Published on: September 4, 2012

42.7K

Radiopharmaceuticals for Bone Metastases.

Andrew W Smith1, Benjamin A Greenberger2, Robert B Den2

  • 1Departments of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY.

Seminars in Radiation Oncology
|November 28, 2020
PubMed
Summary

Radioisotopes like radium-223 offer improved survival for metastatic castrate-resistant prostate cancer (mCRPC) bone metastases. Research explores combining alpha and beta therapies with systemic agents for optimal mCRPC treatment.

More Related Videos

Multi-modal Imaging of Angiogenesis in a Nude Rat Model of Breast Cancer Bone Metastasis Using Magnetic Resonance Imaging, Volumetric Computed Tomography and Ultrasound
12:23

Multi-modal Imaging of Angiogenesis in a Nude Rat Model of Breast Cancer Bone Metastasis Using Magnetic Resonance Imaging, Volumetric Computed Tomography and Ultrasound

Published on: August 14, 2012

14.6K
Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
07:00

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis

Published on: September 26, 2016

17.1K

Related Experiment Videos

Last Updated: Nov 28, 2025

Models of Bone Metastasis
08:49

Models of Bone Metastasis

Published on: September 4, 2012

42.7K
Multi-modal Imaging of Angiogenesis in a Nude Rat Model of Breast Cancer Bone Metastasis Using Magnetic Resonance Imaging, Volumetric Computed Tomography and Ultrasound
12:23

Multi-modal Imaging of Angiogenesis in a Nude Rat Model of Breast Cancer Bone Metastasis Using Magnetic Resonance Imaging, Volumetric Computed Tomography and Ultrasound

Published on: August 14, 2012

14.6K
Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
07:00

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis

Published on: September 26, 2016

17.1K

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiopharmaceutical Therapy

Background:

  • Bone metastases present challenges for focal radiotherapy due to multifocality.
  • Systemic targeted therapies, particularly radioisotopes, offer potential for diffuse bone disease.
  • Early beta-emitters (Strontium-89, Samarium-153) showed pain control; alpha-emitter Radium-223 improved survival in metastatic castrate-resistant prostate cancer (mCRPC).

Purpose of the Study:

  • To review the clinical utility and paradigms of alpha- and beta-emitting radioisotopes in mCRPC.
  • To discuss the mechanisms, clinical trials, and use of concurrent therapies.
  • To address uncertainties regarding combination therapies with current systemic agents.

Main Methods:

  • Narrative review of existing literature on alpha- and beta-emitting radioisotopes for bone metastases.
  • Analysis of fundamental antineoplastic mechanisms and early clinical trial data.
  • Discussion of concurrent antiresorptive therapies and ongoing clinical trials.

Main Results:

  • Alpha-emitters like Radium-223 have demonstrated improved overall survival in mCRPC.
  • Beta-emitters have shown efficacy in pain control for bone metastases.
  • Combinatorial use with current systemic agents requires further investigation for safety and efficacy.

Conclusions:

  • Radioisotopes are valuable tools in the mCRPC treatment arsenal, offering survival and pain benefits.
  • Optimizing the use of alpha- and beta-emitting therapies, potentially in combination, is crucial.
  • Further research is needed to establish best practices for integrating these agents with modern systemic therapies.